Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy

被引：12
作者：
Weart, Thomas C. [1 ]
Miller, Kenneth D. [1 ]
Simone, Charles B., II [1 ]
机构：
[1] Univ Maryland, Med Ctr, Marlene & Stewart Greenebaum Comprehens Canc Ctr, 22 S Greene St,S9D10, Baltimore, MD 21201 USA
来源：
CANCER MANAGEMENT AND RESEARCH | 2018年 / 10卷
关键词：
BRAF mutation; MEK; NSCLC; lung cancer; dabrafenib; trametinib; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; MEK INHIBITION; BRAF MUTATIONS; MULTICENTER; CISPLATIN; MELANOMA; COMBINATION; RESISTANCE; KINASES;
D O I：
10.2147/CMAR.S142269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS-RAF-MEK-MAPK pathway, specifically the BRAF V600E mutation, have become an important target for the subset of NSCLC patients with this mutation. This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation.
引用
收藏
页码：647 / 652
页数：6
相关论文
共 41 条
  • [1] [Anonymous], 1973, SEER RES DAT 1973 20
  • [2] Dabrafenib: First Global Approval
    Ballantyne, Anita D.
    Garnock-Jones, Karly P.
    [J]. DRUGS, 2013, 73 (12) : 1367 - 1376
  • [3] Bonomi P, 1996, P AN M AM SOC CLIN, V15, P382
  • [4] Chan M, 2013, J CLIN ONCOL, V31
  • [5] Mechanisms of regulating the Raf kinase family
    Chong, H
    Vikis, HG
    Guan, KL
    [J]. CELLULAR SIGNALLING, 2003, 15 (05) : 463 - 469
  • [6] Cui GH, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006552, 10.1097/md.0000000000006552]
  • [7] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [8] Molecular pathology of thyroid cancer: diagnostic and clinical implications
    Fagin, James A.
    Mitsiades, Nicholas
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) : 955 - 969
  • [9] B-Raf Inhibition in the Clinic: Present and Future
    Fiskus, Warren
    Mitsiades, Nicholas
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 29 - 43
  • [10] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
    Flaherty, Keith T.
    Robert, Caroline
    Hersey, Peter
    Nathan, Paul
    Garbe, Claus
    Milhem, Mohammed
    Demidov, Lev V.
    Hassel, Jessica C.
    Rutkowski, Piotr
    Mohr, Peter
    Dummer, Reinhard
    Trefzer, Uwe
    Larkin, James M. G.
    Utikal, Jochen
    Dreno, Brigitte
    Nyakas, Marta
    Middleton, Mark R.
    Becker, Juergen C.
    Casey, Michelle
    Sherman, Laurie J.
    Wu, Frank S.
    Ouellet, Daniele
    Martin, Anne-Marie
    Patel, Kiran
    Schadendorf, Dirk
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) : 107 - 114
12345